![Jeffrey Edwards](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Edwards
Direktor/Vorstandsmitglied bei FIBROGEN, INC.
Vermögen: 320 881 $ am 31.05.2024
Aktive Positionen von Jeffrey Edwards
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FIBROGEN, INC. | Direktor/Vorstandsmitglied | 28.10.2015 | - |
Independent Dir/Board Member | 28.10.2015 | - | |
BIO-RAD LABORATORIES, INC. | Direktor/Vorstandsmitglied | 25.04.2017 | - |
Independent Dir/Board Member | 25.04.2017 | - | |
CLEARSIDE BIOMEDICAL, INC. | Direktor/Vorstandsmitglied | 26.09.2018 | - |
Independent Dir/Board Member | 26.09.2018 | - | |
LIFECORE BIOMEDICAL, INC. | Direktor/Vorstandsmitglied | 14.10.2020 | - |
Independent Dir/Board Member | 14.10.2020 | - | |
Serica Technologies, Inc.
![]() Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | Direktor/Vorstandsmitglied | 25.04.2011 | - |
Finanzdirektor/CFO | 25.04.2011 | - | |
MAP Pharmaceuticals LLC
![]() MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Direktor/Vorstandsmitglied | 01.03.2013 | - |
Viamet Pharmaceuticals Corp.
![]() Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - | |
Viamet Pharmaceuticals, Inc.
![]() Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | - | - |
BioTheryX, Inc.
![]() BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Direktor/Vorstandsmitglied | 18.09.2019 | - |
Karriereverlauf von Jeffrey Edwards
Ehemalige bekannte Positionen von Jeffrey Edwards
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Jeffrey Edwards
Muhlenberg College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 13 |
Belgien | 2 |
Operativ
Director/Board Member | 9 |
Independent Dir/Board Member | 5 |
Corporate Officer/Principal | 3 |
Sektoral
Health Technology | 11 |
Finance | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
FIBROGEN, INC. | Health Technology |
BIO-RAD LABORATORIES, INC. | Health Technology |
CLEARSIDE BIOMEDICAL, INC. | Health Technology |
LIFECORE BIOMEDICAL, INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
Allergan, Inc.
![]() Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Banque Paribas Belgique SA | Finance |
Security Pacific National Bank | Finance |
Serica Technologies, Inc.
![]() Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | Health Technology |
MAP Pharmaceuticals LLC
![]() MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
Viamet Pharmaceuticals Corp.
![]() Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Viamet Pharmaceuticals, Inc.
![]() Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
BioTheryX, Inc.
![]() BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
- Börse
- Insiders
- Jeffrey Edwards
- Erfahrung